SENTIS™ HRD Score Test

SENTIS™ Homologous Recombination Deficiency (HRD) test expands potential population that can possibly benefit from PARP inhibitors treatments  through assessing genomic instability indicators in cancer cells. Using SNP array method, the panel detects HRD indicators variation including telomere allelic imbalance (TAI), loss of heterozygosity (LOH) and large-scale state transition (LST), and bioinformatics analysis is performed based on BGI database.

>50% of ovarian cancer patients are HRD-positive!
Sample Requirement

Tumor tissue (Tumour cell content  > 30%)

10-12 unstained FFPE sections

Control sample:

  • 5ml peripheral blood in EDTA tube
  • 1 H&E tissue section (optional)
Compared with BCRA1/2 gene testing, HRD Score testing can screen out 36.62% more population that will be benefit from PARP inhibitors.